Calendar - COVID Frontline

Patient Toolkit

Menu

Patient Toolkit

Patient Toolkit

Kit de herramientas para pacientes

Menu

Patient Toolkit

Patient Toolkit

Tackling COVID-19 and its Viral Variants on the Frontline with New Vaccines and Novel Monoclonal Antibody Treatments

Jun 2 2021 @ 4:23 pm – Jun 2 2022 @ 5:23 pm

Welcome to Covid Frontline

COVID Frontline is a comprehensive and up-to-date resource center that helps clinicians and patients stay informed of the latest developments in the management of COVID-19. Click on the buttons below to learn more about emerging monoclonal antibody therapies, vaccines, and treatment options for the care of hospitalized and nonhospitalized patients with COVID-19.

Clinical Toolkit

Patient Toolkit

This activity is provided by Med Learning Group. This activity is co-provided by Ultimate Medical Academy/CCM.
This activity is supported by educational grants from AbbVie, Astellas, Genentech, Lilly, Merck & Co., Inc., Pfizer and Regeneron Pharmaceuticals, Inc

Copyright © 2021 Med Learning Group. Website by Divigner. All Rights Reserved.

Categories: ECHOS Online Programs

COVID-19 Frontline: An Innovative View of Monoclonal Therapies and Vaccines for COVID-19: Educating Patients on the Mechanism of Action, Safety, and Efficacy of Emerging Agents

Jun 2 2021 @ 4:50 pm – Jun 2 2022 @ 5:50 pm

Welcome to Covid Frontline

COVID Frontline is a comprehensive and up-to-date resource center that helps clinicians and patients stay informed of the latest developments in the management of COVID-19. Click on the buttons below to learn more about emerging monoclonal antibody therapies, vaccines, and treatment options for the care of hospitalized and nonhospitalized patients with COVID-19.

Clinical Toolkit

Patient Toolkit

This activity is provided by Med Learning Group. This activity is co-provided by Ultimate Medical Academy/CCM.
This activity is supported by educational grants from AbbVie, Astellas, Genentech, Lilly, Merck & Co., Inc., Pfizer and Regeneron Pharmaceuticals, Inc

Copyright © 2021 Med Learning Group. Website by Divigner. All Rights Reserved.

Categories: ECHOS Online Programs

Digital Learning Lab | COVID-19 Frontline: An Innovative View of Monoclonal Therapies and Vaccines for COVID-19: Educating Patients on the Mechanism of Action, Safety, and Efficacy of Emerging Agents

Jun 2 2021 @ 5:20 pm – Jun 2 2022 @ 6:20 pm

Welcome to Covid Frontline

COVID Frontline is a comprehensive and up-to-date resource center that helps clinicians and patients stay informed of the latest developments in the management of COVID-19. Click on the buttons below to learn more about emerging monoclonal antibody therapies, vaccines, and treatment options for the care of hospitalized and nonhospitalized patients with COVID-19.

Clinical Toolkit

Patient Toolkit

This activity is provided by Med Learning Group. This activity is co-provided by Ultimate Medical Academy/CCM.
This activity is supported by educational grants from AbbVie, Astellas, Genentech, Lilly, Merck & Co., Inc., Pfizer and Regeneron Pharmaceuticals, Inc

Copyright © 2021 Med Learning Group. Website by Divigner. All Rights Reserved.

Categories: ECHOS Online Programs

Digital Learning Lab | COVID-19 Frontline Therapies: Navigating Through This Health Crisis and Optimizing Patient Care

Jun 11 2021 @ 5:30 pm – Jun 11 2022 @ 6:30 pm

Welcome to Covid Frontline

COVID Frontline is a comprehensive and up-to-date resource center that helps clinicians and patients stay informed of the latest developments in the management of COVID-19. Click on the buttons below to learn more about emerging monoclonal antibody therapies, vaccines, and treatment options for the care of hospitalized and nonhospitalized patients with COVID-19.

Clinical Toolkit

Patient Toolkit

This activity is provided by Med Learning Group. This activity is co-provided by Ultimate Medical Academy/CCM.
This activity is supported by educational grants from AbbVie, Astellas, Genentech, Lilly, Merck & Co., Inc., Pfizer and Regeneron Pharmaceuticals, Inc

Copyright © 2021 Med Learning Group. Website by Divigner. All Rights Reserved.

Categories: ECHOS Online Programs

New COVID-19 Frontline Infusion Therapies: Optimizing Health Outcomes for High-Risk Patients

Jun 25 2021 @ 3:33 pm – Jun 25 2022 @ 4:33 pm

Welcome to Covid Frontline

COVID Frontline is a comprehensive and up-to-date resource center that helps clinicians and patients stay informed of the latest developments in the management of COVID-19. Click on the buttons below to learn more about emerging monoclonal antibody therapies, vaccines, and treatment options for the care of hospitalized and nonhospitalized patients with COVID-19.

Clinical Toolkit

Patient Toolkit

This activity is provided by Med Learning Group. This activity is co-provided by Ultimate Medical Academy/CCM.
This activity is supported by educational grants from AbbVie, Astellas, Genentech, Lilly, Merck & Co., Inc., Pfizer and Regeneron Pharmaceuticals, Inc

Copyright © 2021 Med Learning Group. Website by Divigner. All Rights Reserved.

Categories: ECHOS Online Programs

COVID-19 VA Grand Rounds Enduring Activity: Navigating Through This Health Crisis

Jul 12 2021 @ 7:00 am – Jul 12 2022 @ 8:00 am

Welcome to Covid Frontline

COVID Frontline is a comprehensive and up-to-date resource center that helps clinicians and patients stay informed of the latest developments in the management of COVID-19. Click on the buttons below to learn more about emerging monoclonal antibody therapies, vaccines, and treatment options for the care of hospitalized and nonhospitalized patients with COVID-19.

Clinical Toolkit

Patient Toolkit

This activity is provided by Med Learning Group. This activity is co-provided by Ultimate Medical Academy/CCM.
This activity is supported by educational grants from AbbVie, Astellas, Genentech, Lilly, Merck & Co., Inc., Pfizer and Regeneron Pharmaceuticals, Inc

Copyright © 2021 Med Learning Group. Website by Divigner. All Rights Reserved.

Categories: ECHOS Online Programs

COVID-19 Frontline Therapies: Navigating Through This Health Crisis and Optimizing Patient Care

Aug 11 2021 @ 7:00 am – Aug 11 2022 @ 8:00 am

Welcome to Covid Frontline

COVID Frontline is a comprehensive and up-to-date resource center that helps clinicians and patients stay informed of the latest developments in the management of COVID-19. Click on the buttons below to learn more about emerging monoclonal antibody therapies, vaccines, and treatment options for the care of hospitalized and nonhospitalized patients with COVID-19.

Clinical Toolkit

Patient Toolkit

This activity is provided by Med Learning Group. This activity is co-provided by Ultimate Medical Academy/CCM.
This activity is supported by educational grants from AbbVie, Astellas, Genentech, Lilly, Merck & Co., Inc., Pfizer and Regeneron Pharmaceuticals, Inc

Copyright © 2021 Med Learning Group. Website by Divigner. All Rights Reserved.

Categories: ECHOS Online Programs

New Vaccines and Novel Monoclonal Antibody Treatments on the Frontline of COVID-19

Oct 11 2021 @ 8:43 am – Oct 11 2022 @ 9:43 am

Welcome to Covid Frontline

COVID Frontline is a comprehensive and up-to-date resource center that helps clinicians and patients stay informed of the latest developments in the management of COVID-19. Click on the buttons below to learn more about emerging monoclonal antibody therapies, vaccines, and treatment options for the care of hospitalized and nonhospitalized patients with COVID-19.

Clinical Toolkit

Patient Toolkit

This activity is provided by Med Learning Group. This activity is co-provided by Ultimate Medical Academy/CCM.
This activity is supported by educational grants from AbbVie, Astellas, Genentech, Lilly, Merck & Co., Inc., Pfizer and Regeneron Pharmaceuticals, Inc

Copyright © 2021 Med Learning Group. Website by Divigner. All Rights Reserved.

Categories: ECHOS Online Programs

Putting Novel Antibody Therapies for COVID-19 in Clinical Context: Evaluating Clinical Data, Monitoring, Infusion Best Practices, and Pediatric EUAs

Mar 30 2022 @ 9:29 pm – Mar 30 2023 @ 10:29 pm

Welcome to Covid Frontline

COVID Frontline is a comprehensive and up-to-date resource center that helps clinicians and patients stay informed of the latest developments in the management of COVID-19. Click on the buttons below to learn more about emerging monoclonal antibody therapies, vaccines, and treatment options for the care of hospitalized and nonhospitalized patients with COVID-19.

Clinical Toolkit

Patient Toolkit

This activity is provided by Med Learning Group. This activity is co-provided by Ultimate Medical Academy/CCM.
This activity is supported by educational grants from AbbVie, Astellas, Genentech, Lilly, Merck & Co., Inc., Pfizer and Regeneron Pharmaceuticals, Inc

Copyright © 2021 Med Learning Group. Website by Divigner. All Rights Reserved.

Categories: Online Programs Podcast

Putting Novel Antibody Therapies for COVID-19 in Clinical Context: Evaluating Clinical Data, Monitoring, Infusion Best Practices, and Pediatric EUAs

Apr 8 2022 @ 8:13 pm – Apr 8 2023 @ 9:13 pm

Welcome to Covid Frontline

COVID Frontline is a comprehensive and up-to-date resource center that helps clinicians and patients stay informed of the latest developments in the management of COVID-19. Click on the buttons below to learn more about emerging monoclonal antibody therapies, vaccines, and treatment options for the care of hospitalized and nonhospitalized patients with COVID-19.

Clinical Toolkit

Patient Toolkit

This activity is provided by Med Learning Group. This activity is co-provided by Ultimate Medical Academy/CCM.
This activity is supported by educational grants from AbbVie, Astellas, Genentech, Lilly, Merck & Co., Inc., Pfizer and Regeneron Pharmaceuticals, Inc

Copyright © 2021 Med Learning Group. Website by Divigner. All Rights Reserved.

Categories: ECHOS Online Programs

June 2021 – April 2022 Jun 2021 – Apr 2022

This activity is co-provided by Ultimate Medical Academy/Complete Conference Management (CCM).
This activity is supported by educational grants from AbbVie, Astellas, Genentech, Lilly, Merck & Co., Inc., Pfizer and Regeneron Pharmaceuticals, Inc.

Copyright © 2019 Med Learning Group. Website by Divigner. All Rights Reserved.

Esta actividad es co-proporcionada por Ultimate Medical Academy / Complete Conference Management (CCM).
Esta actividad cuenta con el apoyo de subvenciones educativas de AbbVie, Astellas, Genentech, Lilly, Merck & Co., Inc., Pfizer y Regeneron Pharmaceuticals, Inc.

Copyright © 2019 Med Learning Group. Sitio web de Divigner. Todos los derechos reservados.

Updates in the Treatment and Prevention of COVID-19

EUA of Bamlanivimab Plus Etesevimab Expanded to Include Younger Pediatric Patients

The emergency use authorization (EUA) for bamlanivimab plus etesevimab now includes an indication for treatment and post-exposure prophylaxis for children and newborn babies who are at high risk for severe disease. The expansion of the EUA is supported by a trial of 125 pediatric patients with at least one risk factor for severe illness; the study had safety and efficacy data similar to findings for adolescents and adults.

For more information visit www.fda.gov/news-events/press-announcements/fda-expands-authorization-two-monoclonal-antibodies-treatment-and-post-exposure-prevention-covid-19

Oral Antiviral Therapies With Emergency Use Authorization (EUA) for COVID-19

Two new oral antiviral therapies received emergency use authorization (EUA) for COVID-19: Paxlovid™ (nirmatrelvir tablets and ritonavir tablets, co-packaged) and molnupiravir. Both therapies are authorized for the treatment of mild-to-moderate COVID-19 in certain people who are at high risk of progressing to severe illness.

In the EPIC-HR clinical trial, nirmatrelvir/ritonavir significantly reduced the risk of hospitalization or death from any cause by 88% compared with placebo. This treatment is indicated for adults and pediatric patients, 12 years of age and older who weigh at least 40 kilograms. Side effects include an impaired sense of taste, diarrhea, high blood pressure, and muscle aches. The safety and effectiveness of this combination therapy continue to be evaluated.

The main outcome measure of the MOVe-OUT trial of molnupiravir was the percentage of people who were hospitalized or died due to any cause during 29 days of follow-up. Compared with 9.7% of people who received placebo, 6.8% of those in the molnupiravir group were hospitalized or died. One person who received molnupiravir died versus nine people in the placebo group. Molnupiravir is not recommended for pregnant women or for those people younger than 18 years of age because of its effect on bone and cartilage growth.

For more information regarding the EUA for these oral antivirals, visit the following FDA URLs:

www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-oral-antiviral-treatment-covid-19

www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-oral-antiviral-treatment-covid-19-certain

FDA Authorized Emergency Use Authorization (EUA) for Long-Acting Monoclonal Antibodies as Pre-Exposure Prophylaxis of COVID-19

Evusheld™ (tixagevimab co-packaged with cilgavimab and administered together) has been granted EUA for the prevention of COVID-19 in certain people with compromised immune systems or with a history of severe adverse reactions to a COVID-19 vaccine or any of its components. This combination is not meant to be a substitute for vaccination for those who have no contraindications to a COVID-19 vaccine.

The PROVENT clinical trial demonstrated a 77% reduction in the risk of developing COVID-19 compared with placebo, and protection appears to have been maintained through six months. Safety and efficacy of the tixagevimab/cilgavimab combination continues to be investigated.

For more information, visit www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-new-long-acting-monoclonal-antibodies-pre-exposure